Randomized trial · people

VIP (aviptadil) missed its main goal in critical COVID-19 trial

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In critical COVID-19, IV VIP did not beat placebo on the trial's main outcome, though survival looked better; it says nothing about other uses of VIP.

Kind
Randomized trial
Studied in
People
Number studied
196
Published
2022
Journal
Crit Care Med

What they tested

The team tested whether aviptadil, a synthetic form of VIP given by IV, could help patients with COVID-19 respiratory failure survive and recover better than placebo.

How the study was done

A randomized, placebo-controlled trial at 10 U.S. hospitals in 196 patients with COVID-19 respiratory failure. Patients were assigned 2:1 to 3 days of IV aviptadil or placebo (a dummy infusion) and followed for 60 days.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking VIP? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The main goal was being alive and free of respiratory failure at day 60, and aviptadil fell short: its OR (odds ratio, which compares the chance of an outcome on the drug with the chance on placebo) was 1.6, with a 95% CI of 0.86-3.11, so there was no clear difference from placebo. Survival alone at day 60 was better with aviptadil (OR 2.0; 95% CI 1.1-3.9; p = 0.035), and by day 3 the respiratory distress ratio improved and interleukin 6, an inflammation signal, fell (p = 0.02). In subgroups, patients on high-flow nasal oxygen at the start were more likely to reach the main goal (p = 0.039), and those on mechanical ventilation had 10-fold higher odds of survival with the drug (p = 0.031); the team saw no drug-related serious side effects.

What it doesn’t show

The trial failed its main outcome, so the survival and subgroup results are secondary findings that can't settle the question alone. It studied only hospitalized patients with critical COVID-19 who got a short IV course.

The paper

Youssef et al. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Crit Care Med. 2022.

The compound

More studies on VIP

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking VIP? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo